Oral cancer: Current role of radiotherapy and chemotherapy

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 18, Issue 2, 2013, Pages

  Huang, Shao Hui ^b   O'Sullivan, Brian ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

Chemoradiotherapy; Oral cavity cancer; Radiotherapy; Treatment

Indexed keywords

EPIDERMAL GROWTH FACTOR;

ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); MOUTH CANCER; PREVALENCE; RADIATION DOSE; RISK FACTOR;

COMBINED MODALITY THERAPY; HUMANS; MOUTH NEOPLASMS;

EID: 84874909578     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: 10.4317/medoral.18772     Document Type: Article

References (55)

1. Bessell A, Glenny AM, Furness S, Clarkson JE, Oliver R, Conway DI, et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database Syst Rev. 2011;9:CD006205.
2. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843-50.
3. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937-44.
4. Shrime MG, Gullane PJ, Dawson L, Kim J, Gilbert RW, Irish JC, et al. The impact of adjuvant radiotherapy on survival in T1-2N1 squamous cell carcinoma of the oral cavity. Arch Otolaryngol Head Neck Surg. 2010;136:225-8.
5. Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993;26:3-11.
6. Langendijk JA, Slotman BJ, van der Waal I, Doornaert P, Berkof J, Leemans CR. Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Cancer. 2005;104:1408-1417.
7. Brown JS, Shaw RJ, Bekiroglu F, Rogers SN. Systematic review of the current evidence in the use of postoperative radiotherapy for oral squamous cell carcinoma. Br J Oral Maxillofac Surg. 2012;50:481-489.
8. Huang TY, Hsu LP, Wen YH, Huang TT, Chou YF, Lee CF, et al. Predictors of locoregional recurrence in early stage oral cavity cancer with free surgical margins. Oral Oncol. 2010;46:49-55.
9. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Does adjuvant radiation therapy improve outcomes in pT1-3N0 oral cavity cancer with tumor-free margins and perineural invasion? Int J Radiat Oncol Biol Phys. 2008;71:371-6.
10. Huang SH, Hwang D, Lockwood G, Goldstein DP, O'Sullivan B. Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity: a meta-analysis of reported studies. Cancer. 2009;115:1489-1497.
11. Liao CT, Lin CY, Fan KH, Wang HM, Ng SH, Lee LY, et al. Identification of a high-risk group among patients with oral cavity squamous cell carcinoma and pT1-2N0 disease. Int J Radiat Oncol Biol Phys. 2012;82:284-90.
12. Moergel M, Jahn-Eimermacher A, Krummenauer F, Reichert TE, Wagner W, Wendt TG, et al. Effectiveness of adjuvant radiotherapy in patients with oropharyngeal and floor of mouth squamous cell carcinoma and concomitant histological verification of singular ipsilateral cervical lymph node metastasis (pN1-state)--a prospective multicenter randomized controlled clinical trial using a comprehensive cohort design. Trials. 2009;10:118.
13. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-52.
14. Cooper JS, Pajak TF, Forastiere A, Jacobs J, Fu KK, Ang KK, et al. Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck.1998;20:588-94.
15. Fan KH, Wang HM, Kang CJ, Lee LY, Huang SF, Lin CY, et al. Treatment results of postoperative radiotherapy on squamous cell carcinoma of the oral cavity: coexistence of multiple minor risk factors results in higher recurrence rates. Int J Radiat Oncol Biol Phys. 2010;77:1024-9.
16. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol. 2008;15:915-22.
17. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys. 1997;39:137-48.
18. Looser KG, Shah JP, Strong EW. The significance of "positive" margins in surgically resected epidermoid carcinomas. Head Neck Surg. 1978;1:107-111.
19. Batsakis JG. Surgical excision margins: a pathologist's perspective. Adv Anat Pathol. 1999;6:140-148.
20. Binahmed A, Nason RW, Abdoh AA. The clinical significance of the positive surgical margin in oral cancer. Oral Oncol. 2007;43:780-784.
21. Chen PY, Chen HH, Hsiao JR, Yang MW, Hsueh WT, Tasi ST, et al. Intensity-modulated radiotherapy improves outcomes in postoperative patients with squamous cell carcinoma of the oral cavity. Oral Oncol. 2012;48:747-52.
22. Guillemaud JP, Patel RS, Goldstein DP, Higgins KM, Enepekides DJ. Prognostic impact of intraoperative microscopic cut-through on frozen section in oral cavity squamous cell carcinoma. J Otolaryngol Head Neck Surg. 2010;39:370-7.
23. Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol. 2003;21:555-63.
24. Daly ME, Le QT, Kozak MM, Maxim PG, Murphy JD, Hsu A, et al. Intensity-modulated radiotherapy for oral cavity squamous cell carcinoma: patterns of failure and predictors of local control. Int J Radiat Oncol Biol Phys. 2011;80:1412-22.
25. Langendijk JA, de Jong MA, Leemans CR, de Bree R, Smeele LE, Doornaert P, et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time. Int J Radiat Oncol Biol Phys. 2003;57:693-700.
26. Studer G, Zwahlen RA, Graetz KW, Davis BJ, Glanzmann C. IMRT in oral cavity cancer. Radiat Oncol. 2007;2:16.
27. Murthy V, Agarwal JP, Laskar SG, Gupta T, Budrukkar A, Pai P, et al. Analysis of prognostic factors in 1180 patients with oral cavity primary cancer treated with definitive or adjuvant radiotherapy. J Cancer Res Ther. 2010;6:282-9.
28. Cohen EE, Baru J, Huo D, Haraf DJ, Crowley M, Witt ME, Blair EA, Weichselbaum RR, Rosen F, Vokes EE, Stenson K. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009;31:1013-21.
29. Pignon JP, le Maître A, Maillard E, Bourhis J. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4-14.
30. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843-54.
31. Mazeron JJ, Ardiet JM, Haie-Méder C, Kovács G, Levendag P, Peiffert D, et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol. 2009;91:150-6.
32. Chakrabarti B, Ghorai S, Basu B, Ghosh SK, Gupta P, Ghosh K, et al. Late nodal metastasis in early-stage node-negative oral cavity cancers after successful sole interstitial brachytherapy: an institutional experience of 42 cases in India. Brachytherapy. 2010;9:254-9.
33. Grabenbauer GG, Rödel C, Brunner T, Schulze-Mosgau S, Strnad V, Müller RG, et al. Interstitial brachytherapy with Ir-192 low-doserate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Review of 318 patients treated between 1985 and 1997. Strahlenther Onkol. 2001;177:338-44.
34. Do L, Puthawala A, Syed N. Interstitial brachytherapy as boost for locally advanced T4 head and neck cancer. Brachytherapy. 2009;8:385-91.
35. Patra NB, Goswami J, Basu S, Chatterjee K, Sarkar SK. Outcomes of high dose rate interstitial boost brachytherapy after external beam radiation therapy in head and neck cancer--an Indian (single institutional) learning experience. Brachytherapy. 2009;8:248-54.
36. Chatani M, Tsuboi K, Yagi M, Fujiwara K, Tachimoto R, Yoshioka H. High dose rate brachytherapy using molds after chemoradiotherapy for oral cavity cancer. Jpn J Radiol. 2012;30:40-4.
37. Lapeyre M, Bollet MA, Racadot S, Geoffrois L, Kaminsky MC, Hoffstetter S, et al. Postoperative brachytherapy alone and combined postoperative radiotherapy and brachytherapy boost for squamous cell carcinoma of the oral cavity, with positive or close margins. Head Neck. 2004;26:216-23.
38. Grimard L, Esche B, Lamothe A, Cygler J, Spaans J. Interstitial low-dose-rate brachytherapy in the treatment of recurrent head and neck malignancies. Head Neck. 2006;28:888-95.
39. Grimard L, Esche B, Lamothe A, Spaans JN. Interstitial brachytherapy in the management of persistent head and neck disease after definitive external beam radiation therapy. Brachytherapy. 2009;8:284-9.
40. Mazeron JJ, Noël G, Simon JM. Head and neck brachytherapy. Semin Radiat Oncol. 2002;12:95-108.
41. Huang SF, Cheng SD, Chien HT, Liao CT, Chen IH, Wang HM, et al. Relationship between epidermal growth factor receptor gene copy number and protein expression in oral cavity squamous cell carcinoma. Oral Oncol. 2012;48:67-72.
42. Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Cheng AJ. Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. Br J Cancer. 2003;89:681-6.
43. Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, et al. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res. 2012;18:2278-89.
44. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-78.
45. Bhide SA, Ahmed M, Newbold K, Harrington KJ, Nutting CM. The role of intensity modulated radiotherapy in advanced oral cavity carcinoma. J Cancer Res Ther. 2012;8 Suppl 1:S67-71.
46. Sher DJ, Thotakura V, Balboni TA, Norris CM, Haddad RI, Posner MR, et al. Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011;81:e215-22.
47. Tsai CJ, Hofstede TM, Sturgis EM, Garden AS, Lindberg ME, Wei Q, et al. Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2013;85:415-20.
48. Balogh JM, Sutherland SE. Osteoradionecrosis of the mandible: a review. J Otolaryngol. 1989;18:245-50.
49. Monnier Y, Broome M, Betz M, Bouferrache K, Ozsahin M, Jaques B. Mandibular osteoradionecrosis in squamous cell carcinoma of the oral cavity and oropharynx: incidence and risk factors. Otolaryngol Head Neck Surg. 2011;144:726-32.
50. O'Sullivan B, Rumble RB, Warde P, Members of the IMRT Indications Expert Panel. Intensity-modulated radiotherapy in the treatment of head and neck cancer. Clin Oncol (R Coll Radiol). 2012;24:474-87.
51. Ben-David MA, Diamante M, Radawski JD, Vineberg KA, Stroup C, Murdoch-Kinch CA, et al. Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys. 2007;68:396-402.
52. Studer G, Studer SP, Zwahlen RA, Huguenin P, Grätz KW, Lütolf UM, et al. Osteoradionecrosis of the mandible: minimized risk profile following intensity-modulated radiation therapy (IMRT). Strahlenther Onkol. 2006;182:283-8.
53. Little M, Schipper M, Feng FY, Vineberg K, Cornwall C, Murdoch-Kinch CA, et al. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys. 2012;83:1007-14.
54. Chen WC, Hwang TZ, Wang WH, Lu CH, Chen CC, Chen CM, et al. Comparison between conventional and intensity-modulated post-operative radiotherapy for stage III and IV oral cavity cancer in terms of treatment results and toxicity. Oral Oncol. 2009;45:505-10.
55. Mishra RC, Singh DN, Mishra TK. Post-operative radiotherapy in carcinoma of buccal mucosa, a prospective randomized trial. Eur J Surg Oncol. 1996;22:502-4.